These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 32951052)

  • 1. Intact and C-Terminal FGF23 Assays-Do Kidney Function, Inflammation, and Low Iron Influence Relationships With Outcomes?
    Sharma S; Katz R; Bullen AL; Chaves PHM; de Leeuw PW; Kroon AA; Houben AJHM; Shlipak MG; Ix JH
    J Clin Endocrinol Metab; 2020 Dec; 105(12):e4875-85. PubMed ID: 32951052
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Iron deficiency, elevated erythropoietin, fibroblast growth factor 23, and mortality in the general population of the Netherlands: A cohort study.
    Eisenga MF; De Jong MA; Van der Meer P; Leaf DE; Huls G; Nolte IM; Gaillard CAJM; Bakker SJL; De Borst MH
    PLoS Med; 2019 Jun; 16(6):e1002818. PubMed ID: 31170159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Strength of Fibroblast Growth Factor 23 as a Cardiovascular Risk Predictor in Chronic Kidney Disease Weaken by ProBNP Adjustment.
    Emrich IE; Brandenburg V; Sellier AB; Schauerte J; Wiedenroth J; Untersteller K; Lennartz CS; Seiler-Mussler S; Wagenpfeil S; Fliser D; Heine GH
    Am J Nephrol; 2019; 49(3):203-211. PubMed ID: 30808827
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of Fibroblast Growth Factor 23 With Risk of Incident Coronary Heart Disease in Community-Living Adults.
    Panwar B; Judd SE; Wadley VG; Jenny NS; Howard VJ; Safford MM; Gutiérrez OM
    JAMA Cardiol; 2018 Apr; 3(4):318-325. PubMed ID: 29516098
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inflammation and elevated levels of fibroblast growth factor 23 are independent risk factors for death in chronic kidney disease.
    Munoz Mendoza J; Isakova T; Cai X; Bayes LY; Faul C; Scialla JJ; Lash JP; Chen J; He J; Navaneethan S; Negrea L; Rosas SE; Kretzler M; Nessel L; Xie D; Anderson AH; Raj DS; Wolf M;
    Kidney Int; 2017 Mar; 91(3):711-719. PubMed ID: 28017325
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epoetin Beta and C-Terminal Fibroblast Growth Factor 23 in Patients With Chronic Heart Failure and Chronic Kidney Disease.
    Eisenga MF; Emans ME; van der Putten K; Cramer MJ; Diepenbroek A; Velthuis BK; Doevendans PA; Verhaar MC; Joles JA; Bakker SJL; Nolte IM; Braam B; Gaillard CAJM
    J Am Heart Assoc; 2019 Aug; 8(16):e011130. PubMed ID: 31423921
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PTH, FGF23, and Intensive Blood Pressure Lowering in Chronic Kidney Disease Participants in SPRINT.
    Ginsberg C; Craven TE; Chonchol MB; Cheung AK; Sarnak MJ; Ambrosius WT; Killeen AA; Raphael KL; Bhatt UY; Chen J; Chertow GM; Freedman BI; Oparil S; Papademetriou V; Wall BM; Wright CB; Ix JH; Shlipak MG;
    Clin J Am Soc Nephrol; 2018 Dec; 13(12):1816-1824. PubMed ID: 30425104
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inflammation and functional iron deficiency regulate fibroblast growth factor 23 production.
    David V; Martin A; Isakova T; Spaulding C; Qi L; Ramirez V; Zumbrennen-Bullough KB; Sun CC; Lin HY; Babitt JL; Wolf M
    Kidney Int; 2016 Jan; 89(1):135-46. PubMed ID: 26535997
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relation between Red Cell Distribution Width and Fibroblast Growth Factor 23 Cleaving in Patients with Chronic Kidney Disease and Heart Failure.
    van Breda F; Emans ME; van der Putten K; Braam B; van Ittersum FJ; Kraaijenhagen RJ; de Borst MH; Vervloet M; Gaillard CA
    PLoS One; 2015; 10(6):e0128994. PubMed ID: 26079688
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Iron Deficiency and Incident Heart Failure in Older Community-Dwelling Individuals.
    Sharma S; Katz R; Chaves PHM; Hoofnagle AN; Kizer JR; Bansal N; Ganz T; Ix JH
    ESC Heart Fail; 2024 Jun; 11(3):1435-1442. PubMed ID: 38407565
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum Calcitriol Concentrations and Kidney Function Decline, Heart Failure, and Mortality in Elderly Community-Living Adults: The Health, Aging, and Body Composition Study.
    Selamet U; Katz R; Ginsberg C; Rifkin DE; Fried LF; Kritchevsky SB; Hoofnagle AN; Bibbins-Domingo K; Drew D; Harris T; Newman A; Gutiérrez OM; Sarnak MJ; Shlipak MG; Ix JH
    Am J Kidney Dis; 2018 Sep; 72(3):419-428. PubMed ID: 29885925
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of ferric citrate on serum phosphate and fibroblast growth factor 23 among patients with nondialysis-dependent chronic kidney disease: path analyses.
    Block GA; Pergola PE; Fishbane S; Martins JG; LeWinter RD; Uhlig K; Neylan JF; Chertow GM
    Nephrol Dial Transplant; 2019 Jul; 34(7):1115-1124. PubMed ID: 30380116
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Associations between anemia and FGF23 in the CKiD study.
    Thomas E; Klomhaus AM; Laster ML; Furth SL; Warady BA; Salusky IB; Hanudel MR
    Pediatr Nephrol; 2024 Mar; 39(3):837-847. PubMed ID: 37752381
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fibroblast growth factor 23, left ventricular mass, and left ventricular hypertrophy in community-dwelling older adults.
    Jovanovich A; Ix JH; Gottdiener J; McFann K; Katz R; Kestenbaum B; de Boer IH; Sarnak M; Shlipak MG; Mukamal KJ; Siscovick D; Chonchol M
    Atherosclerosis; 2013 Nov; 231(1):114-9. PubMed ID: 24125420
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fibroblast growth factor 23, mineral metabolism and mortality among elderly men (Swedish MrOs).
    Westerberg PA; Tivesten Å; Karlsson MK; Mellström D; Orwoll E; Ohlsson C; Larsson TE; Linde T; Ljunggren Ö
    BMC Nephrol; 2013 Apr; 14():85. PubMed ID: 23587028
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fibroblast growth factor 23, the ankle-brachial index, and incident peripheral artery disease in the Cardiovascular Health Study.
    Garimella PS; Ix JH; Katz R; Chonchol MB; Kestenbaum BR; de Boer IH; Siscovick DS; Shastri S; Hiramoto JS; Shlipak MG; Sarnak MJ
    Atherosclerosis; 2014 Mar; 233(1):91-6. PubMed ID: 24529128
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral Versus Intravenous Iron Supplementation for the Treatment of Iron Deficiency Anemia in Patients on Maintenance Hemodialysis-Effect on Fibroblast Growth Factor-23 Metabolism.
    Fukao W; Hasuike Y; Yamakawa T; Toyoda K; Aichi M; Masachika S; Kantou M; Takahishi SI; Iwasaki T; Yahiro M; Nanami M; Nagasawa Y; Kuragano T; Nakanishi T
    J Ren Nutr; 2018 Jul; 28(4):270-277. PubMed ID: 29703633
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multi-variable biomarker approach in identifying incident heart failure in chronic kidney disease: results from the Chronic Renal Insufficiency Cohort study.
    Janus SE; Hajjari J; Chami T; Mously H; Badhwar AK; Karnib M; Carneiro H; Rahman M; Al-Kindi SG
    Eur J Heart Fail; 2022 Jun; 24(6):988-995. PubMed ID: 35587997
    [TBL] [Abstract][Full Text] [Related]  

  • 19. C-Terminal Fibroblast Growth Factor 23, Iron Deficiency, and Mortality in Renal Transplant Recipients.
    Eisenga MF; van Londen M; Leaf DE; Nolte IM; Navis G; Bakker SJL; de Borst MH; Gaillard CAJM
    J Am Soc Nephrol; 2017 Dec; 28(12):3639-3646. PubMed ID: 28774998
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of Omega-3 Fatty Acid Supplementation on Plasma Fibroblast Growth Factor 23 Levels in Post-Myocardial Infarction Patients with Chronic Kidney Disease: The Alpha Omega Trial.
    de Borst MH; Baia LC; Hoogeveen EK; Giltay EJ; Navis G; Bakker SJL; Geleijnse JM; Kromhout D; Soedamah-Muthu SS
    Nutrients; 2017 Nov; 9(11):. PubMed ID: 29137111
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.